MAP2K7 and breast carcinoma: By activating transforming growth factor-beta (TGF-β) and mitogen-activated protein kinase (MEK)/ERK signaling, SIX1 obviously enriched breast cancer stem population.[13] However, SIX1 level did not have effects on MFS.